These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25002857)

  • 1. Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2.
    Koizumi H; Goto S; Okita S; Morigaki R; Akaike N; Torii Y; Harakawa T; Ginnaga A; Kaji R
    Front Neurol; 2014; 5():98. PubMed ID: 25002857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for central antispastic effect of botulinum toxin type A.
    Matak I
    Br J Pharmacol; 2020 Jan; 177(1):65-76. PubMed ID: 31444910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transynaptic Action of Botulinum Neurotoxin Type A at Central Cholinergic Boutons.
    Caleo M; Spinelli M; Colosimo F; Matak I; Rossetto O; Lackovic Z; Restani L
    J Neurosci; 2018 Nov; 38(48):10329-10337. PubMed ID: 30315128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes.
    Marinelli S; Vacca V; Ricordy R; Uggenti C; Tata AM; Luvisetto S; Pavone F
    PLoS One; 2012; 7(10):e47977. PubMed ID: 23110146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system.
    Mazzocchio R; Caleo M
    Neuroscientist; 2015 Feb; 21(1):44-61. PubMed ID: 24576870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-distance retrograde effects of botulinum neurotoxin A.
    Antonucci F; Rossi C; Gianfranceschi L; Rossetto O; Caleo M
    J Neurosci; 2008 Apr; 28(14):3689-96. PubMed ID: 18385327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals.
    Mukai Y; Shimatani Y; Sako W; Asanuma K; Nodera H; Sakamoto T; Izumi Y; Kohda T; Kozaki S; Kaji R
    Toxicon; 2014 Apr; 81():32-6. PubMed ID: 24495439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A).
    Restani L; Antonucci F; Gianfranceschi L; Rossi C; Rossetto O; Caleo M
    J Neurosci; 2011 Nov; 31(44):15650-9. PubMed ID: 22049408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin type a antinociceptive activity in trigeminal regions involves central transcytosis.
    Nemanić D; Mustapić M; Matak I; Bach-Rojecky L
    Eur J Pharmacol; 2024 Jan; 963():176279. PubMed ID: 38123005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6.
    Moritz MS; Tepp WH; Bradshaw M; Johnson EA; Pellett S
    mSphere; 2018 Oct; 3(5):. PubMed ID: 30355669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum neurotoxin type A subtype 2 confers greater safety than subtype 1 in a rat Parkinson's disease model.
    Itakura M; Kohda T; Kubo T; Semi Y; Nishiyama K; Azuma YT; Nakajima H; Kozaki S; Takeuchi T
    J Vet Med Sci; 2014 Aug; 76(8):1189-93. PubMed ID: 24849052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin's axonal transport from periphery to the spinal cord.
    Matak I; Riederer P; Lacković Z
    Neurochem Int; 2012 Jul; 61(2):236-9. PubMed ID: 22580329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of the dynamic weight bearing test to assess the effects of acute, intramuscularly administered botulinum neurotoxin type A1 in rats.
    Cornet S; Périer C; Wagner S; Andriambeloson E; Pouzet B; Kalinichev M
    Toxicon X; 2020 Sep; 7():100041. PubMed ID: 32550595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.
    Moritz MS; Tepp WH; Inzalaco HN; Johnson EA; Pellett S
    Toxicon; 2019 Sep; 167():20-28. PubMed ID: 31181297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translocation domain of botulinum neurotoxin A subtype 2 potently induces entry into neuronal cells.
    Kohda T; Tsukamoto K; Torii Y; Kozaki S; Mukamoto M
    Microbiol Immunol; 2020 Jul; 64(7):502-511. PubMed ID: 32301520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum neurotoxin A subtype 2 reduces pathological behaviors more effectively than subtype 1 in a rat Parkinson's disease model.
    Itakura M; Kohda T; Kubo T; Semi Y; Azuma YT; Nakajima H; Kozaki S; Takeuchi T
    Biochem Biophys Res Commun; 2014 May; 447(2):311-4. PubMed ID: 24713302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lasting Peripheral and Central Effects of Botulinum Toxin Type A on Experimental Muscle Hypertonia in Rats.
    Šoštarić P; Vukić B; Tomašić L; Matak I
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond neuromuscular activity: botulinum toxin type A exerts direct central action on spinal control of movement.
    Šoštarić P; Matić M; Nemanić D; Lučev Vasić Ž; Cifrek M; Pirazzini M; Matak I
    Eur J Pharmacol; 2024 Jan; 962():176242. PubMed ID: 38048980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injection.
    Cai BB; Francis J; Brin MF; Broide RS
    Neuroscience; 2017 Jun; 352():155-169. PubMed ID: 28389376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant botulinum neurotoxin serotype A1 in vivo characterization.
    Périer C; Martin V; Cornet S; Favre-Guilmard C; Rocher MN; Bindler J; Wagner S; Andriambeloson E; Rudkin B; Marty R; Vignaud A; Beard M; Lezmi S; Kalinichev M
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00857. PubMed ID: 34632725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.